Biblio

Author Title [ Type(Desc)] Year
Filters: Author is McLornan, Donal P  [Clear All Filters]
Journal Article
Gagelmann N, Sureda A, Montoto S, Murray J, Bolaños N, Kenyon M, Beksac M, Schönland S, Hayden P, Scheurer H, et al. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. Lancet Haematol. 2022;9(10):e786-e795.
Drozd-Sokolowska J, Gras L, Zinger N, Zahrani MAl, Passweg J, Byrne J, Ho A, Huang X-J, Kröger N, Mayer J, et al. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2022.
Hernández-Boluda JCarlos, Eikema D-J, Koster L, Kröger N, Robin M, de Witte M, Finke J, Finazzi MChiara, Broers A, Raida L, et al. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplant. 2023.
Robin M, Gras L, Koster L, Gagelmann N, van Gorkom G, Ederr M, Itälä-Remes M, Zuckerman T, Beguin Y, Schaap N, et al. Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT. Br J Haematol. 2023.
Raj K, Eikema D-J, McLornan DP, Olavarria E, Blok H-J, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, et al. Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2018.
Beelen DWilhelm, Iacobelli S, Koster L, Eikema D-J, van Biezen A, Stölzel F, Ciceri F, Bethge W, Dreger P, Wagner-Drouet E-M, et al. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison. Bone Marrow Transplant. 2024.
McLornan DP, Harrison CN. Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms. Br J Haematol. 2020.
Gurnari C, Robin M, Godley LA, Drozd-Sokołowska J, Włodarski MW, Raj K, Onida F, Worel N, Ciceri F, Carbacioglu S, et al. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023.
Passweg JR, Baldomero H, Ciceri F, Corbacioglu S, de la Camara R, Dolstra H, Glass B, Greco R, McLornan DP, Neven B, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplant. 2023.
Polverelli N, Bonneville EF, de Wreede LC, Koster L, Kröger NMartin, Schroeder T, de Latour RPeffault, Passweg J, Sockel K, Broers AEC, et al. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT. Am J Hematol. 2024.
Beksac M, Eikema D-J, Koster L, Hulin C, Poire X, Hamladji R-M, Gromek T, Bazarbachi A, Ozkurt ZNur, Pabst T, et al. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024.
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernández-Boluda JCarlos, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2023.
Yakoub-Agha I, Greco R, Onida F, de la Camara R, Ciceri F, Corbacioglu S, Dolstra H, Glass B, Kenyon M, McLornan DP, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transplant. 2023.
Waszczuk-Gajda A, Gras L, de Wreede LC, Sirait T, Illés Á, Ozkurt ZNur, Snowden JA, Arat M, Bulabois CEric, Niederland J, et al. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2023.
Tamari R, McLornan DP, Ahn KWoo, Estrada-Merly N, Hernández-Boluda JCarlos, Giralt SA, Palmer JM, Gale RPeter, DeFilipp Z, Marks D, et al. A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood Adv. 2023.